Delaware and the attorneys general of 49 other states and the District of Columbia have reached a settlement with Boehringer Ingelheim Pharmaceuticals, Inc. ("BIPI") regarding alleged off-label marketing and deceptive and misleading representations made in BIPI's promotion of four of its prescription drugs: Micardis®, Aggrenox®, Atrovent®, and Combivent®. The settlement resolves allegations that BIPI engaged […]
Source
No comments:
Post a Comment